AOD-9604
Also known as: Anti-Obesity Drug 9604, GH Fragment 176-191 Modified
Overview
AOD-9604 is a modified peptide fragment corresponding to amino acids 176-191 from the C-terminal region of human growth hormone, with a stabilizing tyrosine modification. It was engineered to isolate the fat-metabolizing properties of growth hormone without producing growth-promoting, insulin-sensitizing, or IGF-1-stimulating effects. Preclinical research demonstrates significant fat reduction, particularly visceral and subcutaneous fat, via beta-3 adrenergic receptor upregulation.
Mechanism of Action
AOD-9604 does not bind growth hormone receptors. Instead, it preferentially accumulates in adipose tissue and interacts with beta-3 adrenergic receptors on fat cell membranes. This activates adenylyl cyclase, raising intracellular cAMP levels, which activates protein kinase A, which phosphorylates and activates hormone-sensitive lipase to break down stored triglycerides. Simultaneously, AOD-9604 downregulates lipogenic enzymes, creating dual fat-loss pressure. In obese mice, it restored suppressed beta-3 AR expression to lean levels, confirming the mechanistic link.
Potential Benefits
- Fat reduction without affecting glucose regulation or insulin sensitivity
- Dual mechanism: increases lipolysis while inhibiting lipogenesis
- Selective targeting of visceral and subcutaneous adipose tissue
- No IGF-1 stimulation, avoiding growth-promoting side effects
- Muscle mass preservation during fat loss
- 50%+ reduction in weight gain in obese mouse models over 19 days
- Beta-3 AR receptor upregulation in adipose tissue
Dosage Protocols
The following reflects doses used in published research studies. This is not medical advice. Consult a qualified healthcare professional.
| Typical Range | 300-500 mcg/day |
| Beginner | 300 mcg/day |
| Intermediate | 500 mcg/day |
| Advanced | 500-1000 mcg/day split into two doses |
| Cycle Duration | 4-12 weeks |
| Cycle Off | 4 weeks |
Best dosed in a fasted state or 2-3 hours post-meal to avoid insulin interference with lipolytic signaling. Morning or pre-cardio dosing is common. Does not significantly impact GH or IGF-1 levels at standard doses.
Use our Reconstitution Calculator to determine exact syringe units for your protocol.
Routes of Administration
Subcutaneous Injection High — systemic fat metabolism effects
Most common method. Typical dose 300 mcg daily, injected into abdominal fat. Best on empty stomach in the morning.
Oral (Capsule) Lower — significant first-pass metabolism
Oral formulations exist but require higher doses due to reduced bioavailability. Less common than injection.
Read our full Routes of Administration Guide for detailed comparison of all delivery methods.
Stacking Protocols
Popular research stacks involving AOD-9604:
Fat Loss Stack
Comprehensive fat metabolism protocol. AOD-9604 directly targets adipose tissue while CJC-1295/Ipamorelin elevate GH for enhanced lipolysis without the diabetogenic effects of full-length GH.
Body Recomposition Stack
Fat loss with metabolic and tissue support. AOD-9604 for lipolysis, MOTS-C for insulin sensitivity and mitochondrial function, BPC-157 for joint/tissue protection during intensive training.
Explore our complete Peptide Stacking Guide for more combinations and safety considerations.
Reconstitution
| Typical Vial Size | 2mg, 5mg |
|---|---|
| BAC Water | 1-2ml per 2mg vial |
| Storage | Refrigerate at 2-8°C after reconstitution |
| Shelf Life | 28 days refrigerated |
Need exact syringe measurements?
Amino Acid Sequence
Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (amino acids 176-191 of HGH with Tyr modification)
Side Effects & Safety
- Generally well-tolerated in clinical studies
- Injection site reactions
- Headache reported in some subjects
- No significant cardiovascular or metabolic adverse events at therapeutic doses
Safety & Contraindications
This information is for educational purposes only. Consult a qualified healthcare provider before using any peptide.
Active Malignancy
Pregnancy / Lactation
Bleeding Disorders
Active Skin Infection at Injection Site
FDA Safety Information
FDA Category 2 concerns: significant immunogenicity risk, limited data, serious adverse events.
Pharmacokinetics
| Half-Life | ~30-60 minutes |
|---|---|
| Storage | Store lyophilized peptide at -20°C (long-term) or 2-8°C (short-term, under 30 days). Reconstituted: refrigerate at 2-8°C and use within 28-30 days. Protect from light. Do not freeze reconstituted solution. |
Synergistic Compounds
The following compounds have been studied alongside AOD-9604 for potential complementary or synergistic effects:
Learn More
References & Further Reading
Latest News & Research
View all articles →
FDA PCAC July 2026: What the BPC-157 peptide compounding review really means
FDA’s Pharmacy Compounding Advisory Committee will review seven unapproved peptides in July 2026. What that process means for BPC-157—and what it doesn’t.
FDA signals enforcement against unapproved compounded GLP-1 drugs: what it means for peptide medicine
The FDA says it will restrict GLP-1 APIs used in mass-marketed unapproved compounded drugs and crack down on advertising that calls them generic versions of branded drugs.
Sublingual compounded peptides: Quicksome claims and what the FDA’s July 2026 PCAC review could change
A press release claims needle-free, sublingual delivery for popular compounded peptides—just as the FDA's PCAC prepares a July 2026 review of seven peptides.
Pemvidutide IMPACT 48-Week MASH Data Lands At EASL 2026 Ahead Of Phase 3
Altimmune's pemvidutide hit 32.4% ELF response, 23.7% triglyceride drop, and 54.5% qFibrosis regression in 212-patient F2/F3 MASH IMPACT Phase 2b at EASL 2026.